Intervacc completes evaluation of US strangles strain ahead of Strangvac trial

  • Intervacc completed an evaluation of a US strain of the strangles pathogen ahead of a planned pivotal clinical trial of its Strangvac vaccine aimed at US registration.
  • Results have already been presented, showing the US strain behaved similarly to the strain used in earlier European trials.
  • The outcome supports use of the US strain in the upcoming trial design, with management pointing to lower expected costs and faster execution for the US program.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Intervacc AB published the original content used to generate this news brief via Cision (Ref. ID: 202605220230BITN____UKPR__EN_20260521-BIT-5781-0) on May 22, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.